From charcot to lou gehrig: deciphering selective motor neuron death in als (original) (raw)

• Charcot, J. M. & Joffory, A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch. Physiol. Neurol. Pathol. 2, 744–754 (1869).
  Google Scholar
• Yoshida, S., Mulder, D. W., Kurland, L. T., Chu, C. P. & Okazaki, H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology 5, 61–70 (1986).
  Article CAS PubMed Google Scholar
• Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993).Reported the landmark discovery that mutations in SOD1 are a primary cause of familial ALS.
  Article CAS PubMed Google Scholar
• Hirano, A., Donnenfeld, H., Sasaki, S. & Nakano, I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43, 461–470 (1984).
  Article CAS PubMed Google Scholar
• Hirano, A. et al. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 43, 471–480 (1984).
  Article CAS PubMed Google Scholar
• Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851–1854 (1998).By using mouse genetics to increase or eliminate wild-type SOD1 (and its superoxide dismutase activity) in the presence of a familial, ALS-linked SOD1 mutant that itself had little enzymatic activity, these authors showed that toxicity was independent of SOD1 activity. In addition, they found aggregates containing SOD1 to be a common feature of SOD1-mutant-mediated disease arising from mutations with different chemical properties.
  Article CAS PubMed Google Scholar
• Mulder, D. W., Kurland, L. T., Offord, K. P. & Beard, C. M. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36, 511–517 (1986).
  Article CAS PubMed Google Scholar
• Longo, V. D., Gralla, E. B. & Valentine, J. S. Superoxide dismutase activity is essential for stationary phase survival in Saccharomyces cerevisiae. Mitochondrial production of toxic oxygen species in vivo. J. Biol. Chem. 271, 12275–12280 (1996).
  Article CAS PubMed Google Scholar
• Andersen, P. M., Morita, M. & Brown, R. H. Jr. in Amyotrophic Lateral Sclerosis (eds Brown, R. H., Meininger, V. & Swash, M.) 223–250 (Martin Dunitz, London, 2000).
  Google Scholar
• Gaudette, M., Hirano, M. & Siddique, T. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 83–89 (2000).
  Article CAS PubMed Google Scholar
• Andersen, P. M. Genetics of sporadic ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2, S37–S41 (2001).
  Article CAS PubMed Google Scholar
• Andersen, P. M. et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nature Genet. 10, 61–66 (1995).
  Article CAS PubMed Google Scholar
• Andersen, P. M. et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 119, 1153–1172 (1996).
  Article PubMed Google Scholar
• Deng, H. X. et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261, 1047–1051 (1993).
  Article CAS PubMed Google Scholar
• Orrell, R., De Belleroche, J., Marklund, S., Bowe, F. & Hallewell, R. A novel SOD mutant and ALS. Nature 374, 504–505 (1995).
  Article CAS PubMed Google Scholar
• Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772–1775 (1994).Represents the first report of a mouse model of familial ALS arising from expression of a transgene encoding a familial-ALS-linked SOD1 mutant. Disease arose in this model despite a very significant elevation of overall SOD1 activity, providing the first evidence that the disease cannot be caused by a diminution of SOD1 activity.
  Article CAS PubMed Google Scholar
• Wong, P. C. et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105–1116 (1995).Reported the second set of mouse models of SOD1-mediated disease. Disease arose from a mutant that retained nearly full enzymatic activity. With the initial report from Gurney et al . (reference 16 ), it was concluded that the toxicity of SOD1 mutants must arise from a toxic property of the mutant subunit, not from a reduction in superoxide dismutase activity.
  Article CAS PubMed Google Scholar
• Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H. & Gordon, J. W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 92, 689–693 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Bruijn, L. I. et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327–338 (1997).
  Article CAS PubMed Google Scholar
• Reaume, A. G. et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genet. 13, 43–47 (1996).
  Article CAS PubMed Google Scholar
• Borchelt, D. R. et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl Acad. Sci. USA 91, 8292–8296 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Bowling, A. C. et al. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. J. Neurochem. 64, 2366–2369 (1995).
  Article CAS PubMed Google Scholar
• Cleveland, D. W., Laing, N., Hurse, P. V. & Brown, R. H. Jr. Toxic mutants in Charcot's sclerosis. Nature 378, 342–343 (1995).
  Article CAS PubMed Google Scholar
• Kostic, V., Jackson-Lewis, V., De Bilbao, F., Dubois-Dauphin, M. & Przedborski, S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277, 559–562 (1997).
  Article CAS PubMed Google Scholar
• Vukosavic, S. et al. Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 20, 9119–9125 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Li, M. et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335–339 (2000).By implantation of a pump to slowly release a broad-spectrum caspase inhibitor, this report showed that chronic caspase inhibition can significantly extend the lifespan of mice that develop disease from expression of a familial-ALS-linked SOD1 mutant. This not only confirmed that a cascade of caspase activation was a feature of SOD1-mediated disease, but showed that inhibiting such a cascade can extend lifespan.
  Article CAS PubMed Google Scholar
• Pasinelli, P., Houseweart, M. K., Brown, R. H. Jr & Cleveland, D. W. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 97, 13901–13906 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Guegan, C., Vila, M., Rosoklija, G., Hays, A. P. & Przedborski, S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 21, 6569–6576 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Corson, L. B., Strain, J. J., Culotta, V. C. & Cleveland, D. W. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc. Natl Acad. Sci. USA 95, 6361–6366 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Beckman, J. S., Carson, M., Smith, C. D. & Koppenol, W. H. ALS, SOD and peroxynitrite. Nature 364, 584 (1993).
  Article CAS PubMed Google Scholar
• Ferrante, R. J. et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann. Neurol. 42, 326–334 (1997).
  Article CAS PubMed Google Scholar
• Bruijn, L. I. et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Natl Acad. Sci. USA 94, 7606–7611 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Andrus, P. K., Fleck, T. J., Gurney, M. E. & Hall, E. D. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 71, 2041–2048 (1998).
  Article CAS PubMed Google Scholar
• Beal, M. F. et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42, 644–654 (1997).
  Article CAS PubMed Google Scholar
• Jaarsma, D. et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol. Dis. 7, 623–643 (2000).
  Article CAS PubMed Google Scholar
• Wiedau-Pazos, M. et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271, 515–518 (1996).
  Article CAS PubMed Google Scholar
• Singh, R. J. et al. Reexamination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated Cu,Zn superoxide dismutase mutants and H2O2 . Proc. Natl Acad. Sci. USA 95, 6675–6680 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hall, E. D., Andrus, P. K., Oostveen, J. A., Fleck, T. J. & Gurney, M. E. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J. Neurosci. Res. 53, 66–77 (1998).
  Article CAS PubMed Google Scholar
• Borchelt, D. R. et al. Superoxide dismutase 1 subunits with mutations linked to familial amyotrophic lateral sclerosis do not affect wild-type subunit function. J. Biol. Chem. 270, 3234–3238 (1995).
  Article CAS PubMed Google Scholar
• Crow, J. P., Sampson, J. B., Zhuang, Y., Thompson, J. A. & Beckman, J. S. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J. Neurochem. 69, 1936–1944 (1997).
  Article CAS PubMed Google Scholar
• Estevez, A. G. et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 286, 2498–2500 (1999).
  Article CAS PubMed Google Scholar
• Williamson, T. L. et al. Toxicity of ALS-linked SOD1 mutants. Science 288, 399–400 (2000).
  Article CAS PubMed Google Scholar
• Goto, J. J. et al. Loss of in vitro metal ion binding specificity in mutant copper–zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 275, 1007–1014 (2000).
  Article CAS PubMed Google Scholar
• Facchinetti, F. et al. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience 90, 1483–1492 (1999).
  Article CAS PubMed Google Scholar
• Doroudchi, M. M., Minotti, S., Figlewicz, D. A. & Durham, H. D. Nitrotyrosination contributes minimally to toxicity of mutant SOD1 associated with ALS. Neuroreport 12, 1239–1243 (2001).
  Article CAS PubMed Google Scholar
• Shaw, P. J., Ince, P. G., Falkous, G. & Mantle, D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol. 38, 691–695 (1995).
  Article CAS PubMed Google Scholar
• Bowling, A. C., Schulz, J. B., Brown, R. H. Jr & Beal, M. F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 61, 2322–2325 (1993).
  Article CAS PubMed Google Scholar
• Dal Canto, M. C. & Gurney, M. E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 145, 1271–1279 (1994).
  CAS PubMed PubMed Central Google Scholar
• Kong, J. & Xu, Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18, 3241–3250 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Culotta, V. C. et al. The copper chaperone for superoxide dismutase. J. Biol. Chem. 272, 23469–23472 (1997).
  Article CAS PubMed Google Scholar
• Wong, P. C. et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc. Natl Acad. Sci. USA 97, 2886–2891 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Ferrante, R. J. et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064–2074 (1997).
  Article CAS PubMed Google Scholar
• Johnston, J. A., Dalton, M. J., Gurney, M. E. & Kopito, R. R. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 97, 12571–12576 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Mather, K. et al. Histochemical and immunocytochemical study of ubiquitinated neuronal inclusions in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 19, 141–145 (1993).
  Article CAS PubMed Google Scholar
• Leigh, P. N. et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114, 775–788 (1991).
  Article PubMed Google Scholar
• Leigh, P. N. et al. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci. Lett. 93, 197–203 (1988).
  Article CAS PubMed Google Scholar
• Bruening, W. et al. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Neurochem. 72, 693–699 (1999).
  Article CAS PubMed Google Scholar
• Durham, H. D., Roy, J., Dong, L. & Figlewicz, D. A. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 56, 523–530 (1997).Reported the development of what might be the best in vitro model of SOD1-mediated toxicity. Expression of ALS-linked SOD1 mutants (following injection of genes that encode the mutants) in primary cultured neurons resulted in selective killing of motor, but not sensory, neurons. Mutant SOD1, but not similar injections of genes encoding wild-type SOD1, also gave SOD1 aggregates followed by motor neuron death, leading to the proposal that aggregates might have a role in mutant-mediated toxicity.
  Article CAS PubMed Google Scholar
• Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675–686 (1996).
  Article CAS PubMed Google Scholar
• Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W. D. & Elliott, J. L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20, 660–665 (2000).To examine which cells are the direct targets of toxicity by SOD1 mutants that are normally expressed ubiquitously, transgenic mice were generated to express an ALS-linked SOD1 mutant primarily in astroctyes, but not in motor neurons. This led to astrocytic pathology, but not to motor neuron degeneration or death. This finding indicates that toxicity arising directly from astroctyes is not sufficient for neuronal degeneration without mutant expression in other cell types, most probably the motor neurons themselves.
  Article CAS PubMed PubMed Central Google Scholar
• Williamson, T. L. et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc. Natl Acad. Sci. USA 95, 9631–9636 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Couillard-Despres, S. et al. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc. Natl Acad. Sci. USA 95, 9626–9630 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K. & Rouleau, G. A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 21, 3369–3374 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Carpenter, S. Proximal axonal enlargement in motor neuron disease. Neurology 18, 841–851 (1968).
  Article CAS PubMed Google Scholar
• Xu, Z., Cork, L. C., Griffin, J. W. & Cleveland, D. W. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73, 23–33 (1993).
  Article CAS PubMed Google Scholar
• Cote, F., Collard, J. F. & Julien, J. P. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73, 35–46 (1993).
  Article CAS PubMed Google Scholar
• Couillard-Despres, S., Meier, J. & Julien, J. P. Extra axonal neurofilaments do not exacerbate disease caused by mutant Cu,Zn superoxide dismutase. Neurobiol. Dis. 7, 462–470 (2000).
  Article CAS PubMed Google Scholar
• Nguyen, M. D., Lariviere, R. C. & Julien, J. P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30, 135–147 (2001).
  Article CAS PubMed Google Scholar
• Kong, J. & Xu, Z. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis. Neurosci. Lett. 281, 72–74 (2000).
  Article CAS PubMed Google Scholar
• Williamson, T. L. & Cleveland, D. W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nature Neurosci. 2, 50–56 (1999).
  Article CAS PubMed Google Scholar
• Willard, M. & Simon, C. Modulations of neurofilament axonal transport during the development of rabbit retinal ganglion cells. Cell 35, 551–559 (1983).
  Article CAS PubMed Google Scholar
• Al-Chalabi, A. et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet. 8, 157–164 (1999).
  Article CAS PubMed Google Scholar
• Figlewicz, D. A. et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 3, 1757–1761 (1994).
  Article CAS PubMed Google Scholar
• Tomkins, J. et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 9, 3967–3970 (1998).
  Article CAS PubMed Google Scholar
• De Jonghe, P. et al. Further evidence that neurofilament light chain gene mutations can cause Charcot–Marie–Tooth disease type 2E. Ann. Neurol. 49, 245–249 (2001).
  Article PubMed Google Scholar
• Mersiyanova, I. V. et al. A new variant of Charcot–Marie–Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet. 67, 37–46 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, Z. et al. Subunit composition of neurofilaments specifies axonal diameter. J. Cell Biol. 133, 1061–1069 (1996).
  Article CAS PubMed Google Scholar
• Kawamura, Y. et al. Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 40, 667–675 (1981).
  Article CAS PubMed Google Scholar
• Lee, M. K., Marszalek, J. R. & Cleveland, D. W. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 13, 975–988 (1994).
  Article CAS PubMed Google Scholar
• Tanaka, K. et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699–1702 (1997).
  Article CAS PubMed Google Scholar
• Rothstein, J. D. et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann. Neurol. 30, 224–225 (1991).
  Article CAS PubMed Google Scholar
• Rothstein, J. D. et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28, 18–25 (1990).
  Article CAS PubMed Google Scholar
• Shaw, P. J., Forrest, V., Ince, P. G., Richardson, J. P. & Wastell, H. J. CSF and plasma amino acid levels in motor neuron disease — elevation of CSF glutamate in a subset of patients. Neurodegeneration 4, 209–216 (1995).
  Article CAS PubMed Google Scholar
• Spreux-Varoquaux, O. et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis. A reapprasial using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. (in the press).
• Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R. W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73–84 (1995).Represents the first in a series of reports linking a diminution in glutamate transport (itself arising from loss of the glutamate transporter EAAT2, originally named GLT-1) to sporadic ALS.
  Article CAS PubMed Google Scholar
• Lin, C. L. et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20, 589–602 (1998).
  Article CAS PubMed Google Scholar
• Meyer, T. et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J. Neurol. Sci. 170, 45–50 (1999).
  Article CAS PubMed Google Scholar
• Honig, L. S., Chambliss, D. D., Bigio, E. H., Carroll, S. L. & Elliott, J. L. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls. Neurology 55, 1082–1088 (2000).
  Article CAS PubMed Google Scholar
• Spencer, P. S. et al. Lathyrism: evidence for the role of the neuroexcitatory amino acid BOAA. Lancet 2, 1066–1067 (1986).
  Article CAS PubMed Google Scholar
• Spencer, P. S. et al. Guam ALS–PDC: possible causes. Science 262, 825–826 (1993).
  Article CAS PubMed Google Scholar
• Nagano, I., Wong, P. C. & Rothstein, J. D. Nitration of glutamate transporters in transgenic mice with a familial amyotrophic lateral sclerosis-linked SOD1 mutation. Ann. Neurol. 40, 542 (1996).
  Google Scholar
• Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genet. 28, 131–138 (2001).By using gene replacement methods in mice, these investigators made the very surprising discovery that eliminating the ability of the VEGF gene promoter to respond to hypoxia provokes motor neuron disease in the fraction of animals that survive into adulthood. This raises the possibility that motor neurons are especially sensitive to hypoxia, which might contribute to sporadic disease or represent a genetic risk factor in familial disease.
  Article CAS PubMed Google Scholar
• Rabin, B. A. et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain 122, 1539–1550 (1999).
  Article PubMed Google Scholar
• Chance, P. F. et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. 62, 633–640 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hentati, A. et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15–q22 markers. Neurogenetics 2, 55–60 (1998).
  Article CAS PubMed Google Scholar
• Hadano, S. et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genet. 29, 166–173 (2001).
  Article CAS PubMed Google Scholar
• Yang, Y. et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genet. 29, 160–165 (2001).References 96 and 97 identified mutations in a GEF for an as yet unidentified G protein as the primary cause of a recessively inherited form of ALS linked to human chromosome 2.
  Article CAS PubMed Google Scholar
• Ince, P. et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. 19, 291–299 (1993).
  Article CAS PubMed Google Scholar
• Al-Chalabi, A. et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum. Mol. Genet. 7, 2045–2050 (1998).
  Article CAS PubMed Google Scholar
• Kunst, C. B., Messer, L., Gordon, J., Haines, J. & Patterson, D. Genetic mapping of a mouse modifier gene that can prevent ALS onset. Genomics 70, 181–189 (2000).
  Article CAS PubMed Google Scholar
• Kasarkis, E. J. et al. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52, 1427–1433 (1999).
  Article Google Scholar
• Akbar, M. T. et al. Expression of glial glutamate transporters GLT-1 and GLAST is unchanged in the hippocampus in fully kindled rats. Neuroscience 78, 351–359 (1997).
  Article CAS PubMed Google Scholar
• Borasio, G. D. et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583–586 (1998).
  Article CAS PubMed Google Scholar
• Lai, E. C. et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49, 1621–1630 (1997).
  Article CAS PubMed Google Scholar
• Bensimon, G., Lacomblez, L., Meininger, V. & The ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330, 585–591 (1994).
  Article CAS PubMed Google Scholar
• Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P. & Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347, 1425–1431 (1996).
  Article CAS PubMed Google Scholar
• Klivenyi, P. et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med. 5, 347–350 (1999).
  Article CAS PubMed Google Scholar
• Andreassen, O. A. et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 77, 383–390 (2001).
  Article CAS PubMed Google Scholar
• Shinder, G. A., Lacourse, M. C., Minotti, S. & Durham, H. D. Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 276, 12791–12796 (2001).
  Article CAS PubMed Google Scholar
• Hosler, B. A. et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21–q22. J. Am. Med. Assoc. 284, 1664–1669 (2000).
  Article CAS Google Scholar
• Siddique, T. et al. X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Am. J. Hum. Genet. 63, A308 (1998).
  Google Scholar
• Jung, C. et al. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. 304, 157–160 (2001).
  Article CAS PubMed Google Scholar
• Reinholz, M. M., Merkle, C. M. & Poduslo, J. F. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp. Neurol. 159, 204–216 (1999).
  Article CAS PubMed Google Scholar
• Andreassen, O. A. et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. 168, 419–424 (2001).
  Article CAS PubMed Google Scholar
• Jiang, F., DeSilva, S. & Turnbull, J. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. J. Neurol. Sci. 180, 52–54 (2000).
  Article CAS PubMed Google Scholar
• Andreassen, O. A., Dedeoglu, A., Klivenyi, P., Beal, M. F. & Bush, A. I. _N_-acetyl-l-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 11, 2491–2493 (2000).
  Article CAS PubMed Google Scholar
• Andreassen, O. A. et al. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp. Neurol. 167, 189–195 (2001).
  Article CAS PubMed Google Scholar
• Trieu, V. N., Liu, R., Liu, X. P. & Uckun, F. M. A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 267, 22–25 (2000).
  Article CAS PubMed Google Scholar
• Upton-Rice, M. N., Cudkowicz, M. E., Mathew, R. K., Reif, D. & Brown, R. H. Jr. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice. Ann. Neurol. 45, 413–414 (1999).
  Article CAS PubMed Google Scholar
• Nagano, S., Ogawa, Y., Yanagihara, T. & Sakoda, S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci. Lett. 265, 159–162 (1999).
  Article CAS PubMed Google Scholar
• Gurney, M. E. et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39, 147–157 (1996).
  Article CAS PubMed Google Scholar
• Dugan, L. L. et al. Carboxyfullerenes as neuroprotective agents. Proc. Natl Acad. Sci. USA 94, 9434–9439 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Desnuelle, C., Dib, M., Garrel, C. & Favier, A. A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole–Tocopherol Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2, 9–18 (2001).
  Article CAS PubMed Google Scholar
• Hottinger, A. F., Fine, E. G., Gurney, M. E., Zurn, A. D. & Aebischer, P. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 9, 1548–1551 (1997).
  Article CAS PubMed Google Scholar
• Keep, M., Elmer, E., Fong, K. S. & Csiszar, K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 894, 327–331 (2001).
  Article CAS PubMed Google Scholar
• Barneoud, P. & Curet, O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. 155, 243–251 (1999).
  Article CAS PubMed Google Scholar
• Frank, K. M., Coccia, C., Drachman, D. B. & Rothstein, J. D. COX-2 inhibition prolongs survival in a transgenic mouse model of ALS. Soc. Neurosci. Abstr. 27 (in the press).
• Haverkamp, L. J., Smith, R. G. & Appel, S. H. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Neurol. 36, 253–254 (1994).
  Article CAS PubMed Google Scholar
• Appel, S. H. et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch. Neurol. 45, 381–386 (1988).
  Article CAS PubMed Google Scholar
• Mora, J. S. et al. Intrathecal administration of natural human interferon α in amyotrophic lateral sclerosis. Neurology 36, 1137–1140 (1986).
  Article CAS PubMed Google Scholar
• Patten, E. Therapeutic plasmapheresis and plasma exchange. Crit. Rev. Clin. Lab. Sci. 23, 147–175 (1986).
  Article CAS PubMed Google Scholar
• Harrington, H., Hallett, M. & Tyler, H. R. Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial. Neurology 34, 1083–1085 (1984).
  Article CAS PubMed Google Scholar
• Bradley, W. G. et al. A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology 34, 1079–1082 (1984).
  Article CAS PubMed Google Scholar
• Hallett, M., Harrington, H., Tyler, H. R., Flood, T. & Slater, N. Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy. Adv. Exp. Med. Biol. 174, 575–579 (1984).
  Article CAS PubMed Google Scholar
• Bradley, W. G. Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. Adv. Exp. Med. Biol. 174, 565–573 (1984).
  Article CAS PubMed Google Scholar
• Friedlander, R. M., Brown, R. H., Gagliardini, V., Wang, J. & Yuan, J. Inhibition of ICE slows ALS in mice. Nature 388, 31 (1997).
  Article CAS PubMed Google Scholar
• Prudlo, J. et al. Motor neuron cell death in a mouse model of FALS is not mediated by the p53 cell survival regulator. Brain Res. 879, 183–187 (2000).
  Article CAS PubMed Google Scholar
• Miller, R. G. et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19, 511–515 (1996).
  Article CAS PubMed Google Scholar
• Miller, R. G. et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul. Disord. 6, 101–104 (1996).
  Article CAS PubMed Google Scholar
• Slusher, B. S. et al. Naaladase inhibition increases survival and delays clinical symptoms in SOD transgenic model of ALS. Soc. Neurosci. Abstr. 26, 43.10 (2000).
  Google Scholar
• Sutherland, M. L., Martinowich, K. & Rothstein, J. D. EAAT2 overexpression plays a neuroprotective role in the SOD1 G93A model of amyotrophic lateral sclerosis. Soc. Neurosci. Abstr. 27, (in the press).
• Plaitakis, A., Smith, J., Mandeli, J. & Yahr, M. D. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet 1, 1015–1018 (1988).
  Article CAS PubMed Google Scholar
• Mohajeri, M. H., Figlewicz, D. A. & Bohn, M. C. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum. Gene Ther. 10, 1853–1866 (1999).
  Article CAS PubMed Google Scholar
• Dreibelbis, J. E., Cudkowicz, M. E., Pastuszak, K. A., Smith, E. R. & Brown, R. H. Jr Intracisternal injection of bone morphogenic protein-7 at time of disease onset did not alter disease course in a transgenic mouse model of amyotrophic lateral sclerosis. Soc. Neurosci. Abstr. 26, 865.4 (2000).
  Google Scholar
• Bordet, T. et al. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum. Mol. Genet. 10, 1925–1933 (2001).
  Article CAS PubMed Google Scholar
• Sun, W. & Funakoshi, H. N. T. Hepatocyte growth factor gene transfer improves life span, motor function and motorneuronal death in an ALS transgenic mouse model. Soc. Neurosci. Abstr. 27, (in the press).
• Munsat, T. L. et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 42, 1049–1053 (1992).
  Article CAS PubMed Google Scholar
• Brooks, B. R., Sufit, R. L., Montgomery, G. K., Beaulieu, D. A. & Erickson, L. M. Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. Neurol. Clin. 5, 143–158 (1987).
  Article CAS PubMed Google Scholar
• Caroscio, J. T. et al. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 36, 141–145 (1986).
  Article CAS PubMed Google Scholar
• Trieu, V. N. & Uckun, F. M. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. 258, 685–688 (1999).
  Article CAS PubMed Google Scholar
• Norris, F. H., Denys, E. H. & Fallat, R. J. Trial of octacosanol in amyotrophic lateral sclerosis. Neurology 36, 1263–1264 (1986).
  Article CAS PubMed Google Scholar
• Munsat, T. L., Easterday, C. S., Levy, S., Wolff, S. M. & Hiatt, R. Amantadine and guanidine are ineffective in ALS. Neurology 31, 1054–1055 (1981).
  Article CAS PubMed Google Scholar
• Olarte, M. R., Gersten, J. C., Zabriskie, J. & Rowland, L. P. Transfer factor is ineffective in amyotrophic lateral sclerosis. Ann. Neurol. 5, 385–388 (1979).
  Article CAS PubMed Google Scholar
• Olson, W. H., Simons, J. A. & Halaas, G. W. Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study. Neurology 28, 1293–1295 (1978).
  Article CAS PubMed Google Scholar
• Fareed, G. C. & Tyler, H. R. The use of isoprinosine in patients with amyotrophic lateral sclerosis. Neurology 21, 937–940 (1971).
  Article CAS PubMed Google Scholar
• Ende, N., Weinstein, F., Chen, R. & Ende, M. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci. 67, 53–59 (2000).
  Article CAS PubMed Google Scholar
• Maragakis, N. J. et al. Transplanted neural stem cells are capable of engraftment and diffrentiation in transgenic mutant SOD1 mice. Soc. Neurosci. Abstr. 26, 668.3 (2000).
  Google Scholar